<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>diffuse large B-cell lymphoma &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/diffuse-large-b-cell-lymphoma/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 10:31:55 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>diffuse large B-cell lymphoma &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>TLR9 Levels Predict Outcomes in Lymphoma</title>
		<link>https://bioengineer.org/tlr9-levels-predict-outcomes-in-lymphoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 28 May 2025 13:57:25 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy targets]]></category>
		<category><![CDATA[diffuse large B-cell lymphoma]]></category>
		<category><![CDATA[Lymphoma subtypes]]></category>
		<category><![CDATA[Prognostic biomarkers]]></category>
		<category><![CDATA[TLR9 expression]]></category>
		<guid isPermaLink="false">https://bioengineer.org/tlr9-levels-predict-outcomes-in-lymphoma/</guid>

					<description><![CDATA[Recent advances in lymphoma research have spotlighted the pivotal role of immune receptors in the prognosis and treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common and aggressive forms of non-Hodgkin lymphoma. A groundbreaking study published in BMC Cancer elucidates how the expression of Toll-like receptor 9 (TLR9) intimately correlates with the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">247037</post-id>	</item>
		<item>
		<title>PRDX1 Knockdown Triggers Ferroptosis, Halts Lymphoma</title>
		<link>https://bioengineer.org/prdx1-knockdown-triggers-ferroptosis-halts-lymphoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 30 Apr 2025 09:57:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer therapeutic targets]]></category>
		<category><![CDATA[diffuse large B-cell lymphoma]]></category>
		<category><![CDATA[ferroptosis induction]]></category>
		<category><![CDATA[MAPK/ERK pathway inhibition]]></category>
		<category><![CDATA[PRDX1 knockdown]]></category>
		<guid isPermaLink="false">https://bioengineer.org/prdx1-knockdown-triggers-ferroptosis-halts-lymphoma/</guid>

					<description><![CDATA[In a groundbreaking advancement in cancer research, scientists have uncovered a pivotal mechanism to combat diffuse large B-cell lymphoma (DLBCL), one of the most aggressive and common forms of lymphoma affecting adults worldwide. This study focuses on the role of peroxiredoxin 1 (PRDX1), an antioxidant enzyme, in modulating a specialized form of cell death known [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">242786</post-id>	</item>
	</channel>
</rss>
